SCHEMBL3588034

SCHEMBL3588034

O=C(O)N1CCC(CO)(c2cccc(Cl)c2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.45
SLC6A4 P31645 3/20 0.44
SLC6A3 Q01959 3/20 0.44
HSD11B1 P28845 2/20 0.44
CCR2 P41597 1/20 0.43
CHRM2 P08172 1/20 0.42
CHRM3 P20309 1/20 0.42
SLC6A2 P23975 2/20 0.42
DPP4 P27487 2/20 0.41
DPP8 Q6V1X1 2/20 0.41
DPP9 Q86TI2 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
OPRL1 P41146 1/20 0.40
EPHX2 P34913 1/20 0.40
CCR5 P51681 1/20 0.40
KCNH2 Q12809 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2425376 0.84 HSD11B1 (0.58) TACR1HSD11B1MEN1KMT2AOPRM1
SCHEMBL3599347 0.83 HSD11B1 (0.44) TACR1HSD11B1OPRM1ALDH1A1SMN1; SMN2
SCHEMBL10879330 0.82 SLC6A4 (0.57) SLC6A4SLC6A3HSD11B1CCR2SLC6A2
SCHEMBL700173 0.81 CCR5 (0.54) TACR1HSD11B1MEN1KMT2AOPRD1
SCHEMBL2931056 0.81 OPRM1 (0.52) CCR2MEN1KMT2AOPRM1OPRD1
SCHEMBL3594500 0.80 OPRM1 (0.48) TACR1SLC6A4SLC6A3CCR2SLC6A2
SCHEMBL3582984 0.80 ALDH1A1 (0.52) HSD11B1OPRM1OPRD1OPRK1OPRL1
SCHEMBL23647568 0.80 CNR2 (0.43) SLC6A4SLC6A3HSD11B1CCR2CHRM2
SCHEMBL11963480 0.80 MEN1 (0.42) HSD11B1CCR2CHRM2CHRM3MEN1
SCHEMBL3602790 0.79 SLC6A4 (0.43) TACR1SLC6A4SLC6A3HSD11B1CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383821-B2 NK-1 and serotonin transporter inhibitors BRISTOL-MEYERS SQUIBB COMPANY (US) 2013-02-26 US disclosed
US-20100087434-A1 NK-1 and Serotonin Transporter Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-04-08 US disclosed
US-20070249607-A1 NK-1 AND SEROTONIN TRANSPORTER INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed
WO-2007121389-A2 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AS NK-I AND SEROTONIN TRANSPORTER INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087434-A1 NK-1 and Serotonin Transporter Inhibitors SLC6A4, TPH1, SLC6A2 TACR1 19/4885SLC6A4 1/4885SLC6A3 6/4885
US-20070249607-A1 NK-1 AND SEROTONIN TRANSPORTER INHIBITORS SLC6A4, TPH1, SLC6A2 TACR1 19/4885SLC6A4 1/4885SLC6A3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.